Home » Stocks » DVAX

Dynavax Technologies Corporation (DVAX)

Stock Price: $8.49 USD -0.15 (-1.74%)
Updated Mar 3, 2021 4:00 PM EST - Market closed
After-hours: $8.58 +0.09 (1.06%) Mar 3, 7:55 PM
Market Cap 978.53M
Revenue (ttm) 46.55M
Net Income (ttm) -75.24M
Shares Out 100.75M
EPS (ttm) -0.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $8.49
Previous Close $8.64
Change ($) -0.15
Change (%) -1.74%
Day's Open 8.60
Day's Range 8.31 - 8.83
Day's Volume 3,056,306
52-Week Range 1.80 - 12.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 days ago

EMERYVILLE, Calif., March 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announc...

PRNewsWire - 2 days ago

EMERYVILLE, Calif., March 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that in connection with the commencement of Ms. MacDonald's employment with the...

The Motley Fool - 5 days ago

The biotech's better-than-expected Q4 update pointed to even better days ahead.

The Motley Fool - 5 days ago

The company's collaborations and CpG 1018 vaccine adjuvant are playing an increasingly important role.

PRNewsWire - 6 days ago

EMERYVILLE, Calif., Feb. 25, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today r...

Zacks Investment Research - 1 week ago

Is (DVAX) Outperforming Other Medical Stocks This Year?

The Motley Fool - 1 week ago

The company's hepatitis B virus vaccine won European Union approval.

PRNewsWire - 1 week ago

EMERYVILLE, Calif., Feb. 19, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today a...

Zacks Investment Research - 1 week ago

Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 2 weeks ago

Dynavax Technologies (DVAX) closed the most recent trading day at $9.82, moving +0.41% from the previous trading session.

PRNewsWire - 2 weeks ago

EMERYVILLE, Calif., Feb. 16, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announc...

Zacks Investment Research - 2 weeks ago

Dynavax Technologies (DVAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

PRNewsWire - 3 weeks ago

EMERYVILLE, Calif., Feb. 8, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announce...

PRNewsWire - 3 weeks ago

EMERYVILLE, Calif., Feb. 3, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 7,500...

Benzinga - 3 weeks ago

Dynavax Technologies Corporation (NASDAQ: DVAX) and Serum Institute of India (SII) have dosed the first patient in Phase 1 clinical trial evaluating tetanus, diphtheria, and acellular pertussi...

The Motley Fool - 1 month ago

The biotech had lots of good news.

Benzinga - 1 month ago

Dynavax Technologies Corporation (NASDAQ: DVAX) shares are advancing solidly after the company and Clover Biopharma issued an update on their joint coronavirus vaccine program. What Happened: ...

PRNewsWire - 1 month ago

EMERYVILLE, Calif., Feb. 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today an...

PRNewsWire - 1 month ago

OSLO, Norway AND EMERYVILLE, Calif., Feb. 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel v...

PRNewsWire - 1 month ago

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax's CpG 1018 plus alum in the first half of 2021 with ...

Benzinga - 1 month ago

The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causin...

Other stocks mentioned: CLVS, LCI, NAKD, OPK, PGEN, SENS, TXMD, UMC, VBIV
The Motley Fool - 1 month ago

One is making a COVID-19 vaccine; the other is a fintech.

Other stocks mentioned: LX
PRNewsWire - 1 month ago

TAIPEI, TAIWAN and EMERYVILLE, Calif., Jan. 25, 2021 /PRNewswire/ -- Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO) a biopharmaceutical company focusing on the development and pr...

PRNewsWire - 1 month ago

EMERYVILLE, Calif., Jan. 20, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announc...

The Motley Fool - 1 month ago

The company reported positive clinical results for its hepatitis B vaccine.

PRNewsWire - 1 month ago

EMERYVILLE, Calif., Jan. 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announce...

PRNewsWire - 2 months ago

PUNE, India and EMERYVILLE, Calif., Dec. 23, 2020 /PRNewswire/ -- Further strengthening its fight against COVID-19, Serum Institute of India (SIIPL), the world's largest vaccine manufacturer b...

The Motley Fool - 2 months ago

The company's hepatitis B vaccine received good news in Europe.

PRNewsWire - 2 months ago

EMERYVILLE, Calif., Dec. 10, 2020 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today a...

Business Wire - 2 months ago

CHENGDU, China.--(BUSINESS WIRE)--Clover Biopharmaceuticals, a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines and therapeutics for the...

PRNewsWire - 3 months ago

EMERYVILLE, Calif., Nov. 17, 2020 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today a...

PRNewsWire - 3 months ago

HYDERABAD, India and HOUSTON and EMERYVILLE, Calif., Nov. 16, 2020 /PRNewswire/ -- Biological E. Limited (BE), a Hyderabad-based vaccines and pharmaceutical company, Dynavax Technologies Corpo...

Zacks Investment Research - 3 months ago

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 25.00% and 21.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...

Seeking Alpha - 3 months ago

Dynavax Technologies Corporation (DVAX) CEO Ryan Spencer on Q3 2020 Results - Earnings Call Transcript

InvestorPlace - 4 months ago

Penny stocks have become a popular investment alternative in 2020's volatile corona-economy. Here's a look at 7 penny stock to watch in November.

Other stocks mentioned: CIDM, NEOS, NOK, RYCEY, TTNP, WTRH
Zacks Investment Research - 4 months ago

Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 4 months ago

In the latest trading session, Dynavax Technologies (DVAX) closed at $3.87, marking a -1.53% move from the previous day.

Zacks Investment Research - 4 months ago

Dynavax Technologies (DVAX) closed the most recent trading day at $4.17, moving +0.72% from the previous trading session.

The Motley Fool - 4 months ago

Investors ran out of patience with this COVID-19 stock last month.

Business Wire - 5 months ago

CHENGDU, China--(BUSINESS WIRE)--Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on discovering and developing transformative biologic therapies and vaccines, ...

PRNewsWire - 5 months ago

EMERYVILLE, Calif., Sept. 24, 2020 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today ...

Zacks Investment Research - 5 months ago

Investors need to pay close attention to Dynavax (DVAX) stock based on the movements in the options market lately.

GlobeNewsWire - 5 months ago

Dynavax will provide CpG 1018 to produce up to 190 million doses over a five year period to support Valneva’s contract with the U.K. government

The Motley Fool - 5 months ago

Even these top contenders had a rough end to the summer.

Other stocks mentioned: MRNA, NVAX
The Motley Fool - 5 months ago

Late to the rally in coronavirus vaccine stocks? Consider these four rising biotechs.

Other stocks mentioned: SRNE, VXRT, CVAC
The Motley Fool - 6 months ago

Short-sellers are betting against these stocks big time. But that could set up big opportunities for investors if these biotechs have positive news on the way.

Other stocks mentioned: INO, SRNE
GlobeNewsWire - 6 months ago

EMERYVILLE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines,...

Seeking Alpha - 6 months ago

Dynavax: Ready To Return To Bullish

GlobeNewsWire - 6 months ago

EMERYVILLE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines,...

The Motley Fool - 6 months ago

This biotech has a vaccine for treating hepatitis B and is now tackling COVID-19. But it's still valued at less than $1 billion.

About DVAX

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of ... [Read more...]

Industry
Biotechnology
IPO Date
Feb 19, 2004
CEO
Ryan Spencer
Employees
245
Stock Exchange
NASDAQ
Ticker Symbol
DVAX
Full Company Profile

Financial Performance

In 2020, DVAX's revenue was $46.55 million, an increase of 32.18% compared to the previous year's $35.22 million. Losses were -$75.24 million, -50.69% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for DVAX stock is "Strong Buy." The 12-month stock price forecast is 18.00, which is an increase of 112.01% from the latest price.

Price Target
$18.00
(112.01% upside)
Analyst Consensus: Strong Buy